Equity Overview
Price & Market Data
Price: $0.25
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $215,947
Daily Volume: 0
Performance Metrics
1 Week: -72.60%
1 Month: -73.40%
3 Months: -79.84%
6 Months: -85.88%
1 Year: -99.79%
YTD: -83.77%
Details
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.